In Silico Simulation for Medtech and Biopharma 🗓

Category: Event,Webinar
Apr 25, 2024
Scheduled Event Webinar

In-silico simulation refers to using computer modeling and simulations to predict the behavior of biological systems or processes. It is an increasingly important concept for future medical device and drug development. The benefits of in-silico simulation include lowering costs, reducing animal testing, improving accuracy and safety, and clarifying regulatory pathways. This virtual event aims to illuminate the revolutionary potential of in silico simulation in not only 3D printed devices but also medical technology in general and biopharmaceuticals, led by field experts and thought leaders. From drug discovery to medical device design, participants will gain exclusive insights into how computational modeling and simulation reshape the landscape of healthcare innovation. Witness how virtual prototyping and predictive modeling accelerate novel therapies’ development and optimize treatment strategies. This is an event you must not miss.

Apply to speak or sponsor the event:

Subscribe here to receive event emails.


Simon Sonntag

Dr. Simon Sonntag, CEO & Co-Founder of Virtonomy, has been working in the medical device field for over a decade and has experienced first-hand the challenges of developing and bringing a medical device to market and in clinical practice. Using simulation technology in this field for over ten years now, he has seen the tremendous potential of combining it with digital patient twins – not only to support medical device development but also for the regulatory process and clinical trials. He learned that there is a huge demand from the industry to reduce the time, cost, and risk involved in developing medical products, and these so-called in silico methods can achieve this. Therefore, in 2020 he co-founded Virtonomy with the clear mission to change this industry. Virtonomy stands as a pioneer in the realm of digital patient twins, introducing an end-to-end platform that seamlessly merges real world patient data, artificial intelligence, multiphysics simulations, and predictive analytics to support the medical industry. Virtonomy addresses a significant problem: mitigating the elevated risks, complexities, and time constraints entailed in medical device development, ultimately streamlining the journey to market introduction. Utilizing their advanced technology, they enable medical device developers to conduct product development and testing in the computer, reducing traditional in vivo (animal/human) and in vitro (laboratory) tests with so-called in silico experiments (computer). This makes it possible to explore the interaction of the medical device with physically accurate modeling of the in vitro setup or anatomy of the target population based on real patient data as input. Backed by the FDA and EU Commission, it’s set to cover over 40% of approvals via virtual patients and simulations. The vision of Virtonomy extends to personalized medicine in the future.

Kelsey Crossman

American administrative professional with experience in Business Development in Medical Simulation and Marketing of a European Contract Research Organization managing pharmaceutical trials and medical device studies. Twelve years of experience in complex medical/administrative document management in both private and corporate medical offices and metropolitan area hospitals. Currently, she is the business development manager for Simq GmbH.

Anthony Fejes

Dr. Anthony Fejes holds undergraduate degrees in biochemistry and Independent Studies (Bioinformatics) from the University of Waterloo, as well as a Masters degree in Microbiology & Immunology and a PhD in Bioinformatics from the University of British Columbia. Anthony started his science career as the scientific co-founder and Chief Scientific Officer at Zymeworks Inc, before working for companies such as Fabric Genomics and Tenaya Therapeutics in the Bay Area and New York based SolveBio. His experience pairs over 20 years of professional experience as a programmer with a deep background in genomics, biochemistry and data analysis, as well as a decade of management and startup experience. He is CEO and co-founder at HTuO Biosciences.

Steven Kreuzer

Dr. Steven Kreuzer is a Senior Managing Engineer at Exponent Inc, a scientific and engineering consulting company, based in the Natick, MA (Boston) office. Dr. Kreuzer received his Ph.D. in Mechanical Engineering from the University of Texas at Austin and has been a consultant with Exponent since 2013. He specializes in stress analysis using both experimental and computational approaches, which include finite element analyses and custom mechanical systems. He has worked with numerous companies and projects, supporting everything from design assessments to analyses and tests supporting regulatory submissions. He has been an active participant in the Living Heart Project with Dassault Systèmes since its inception. He serves as a co-lead of the modeling team on the FDA / Dassault ‘ENRICHMENT’ in silico clinical trial. Dr. Kreuzer has applied his expertise to numerous domains, including electronics, aerospace, energy storage, and biomedical applications.

Peter Eltes

Peter Eltes

Dr. Péter Endre Éltes is a board-certified spine surgeon who has authored over 30 scientific publications and supervised multiple medical and engineering students throughout his academic career.
He has been devoted to biomechanical research and clinical practice at the National Center for Spinal Disorders in Budapest, Hungary.
In 2018, Dr. Éltes co-founded and has since led the In Silico Biomechanics Laboratory. Here, he delved into the intricate world of patient-specific spinal care with the vision of establishing novel techniques to enhance the quality of everyday clinical practice. To achieve this, he introduced various cutting-edge technologies such as surgery planning and finite element modeling, all tailored to the individual patient. Additionally, he developed and implemented a workflow to utilize 3D printing for improved patient outcomes.


Zsolt Pásztor

Zsolt Pásztor

Zsolt is a passionate 3D printing specialist in titanium 3D Printing and surface treatment.
Zsolt is co-founder and Managing Director of PREMET, a 3D-printing-focused innovative medical device producer. PREMET specialises in the manufacturing of dental products and custom-made human and veterinary implants. It puts a high emphasis on R&D, covering all steps of production, and has been involved in several international projects. PREMET pays special attention to tests and simulations, including in-silico simulations. PREMET has ISO 9001 and ISO 13485 certifications.
In addition to his professional activities, Zsolt plays a leading role in different organizations. He is a Community Manager at 3DHEALS, co-founder and Vice President of the Hungarian Additive Technology Association, and Leader of the “3D Printing in the Health Sector” working group of MediKlaszter, an accredited Med Tech cluster. In MediKlaszter, he also acts as Director of International Relations.
Zsolt also has sound experience in preparing and implementing international R&D and capacity-building projects.

Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Subscribe here to receive future event emails.